利巴韦林在体外和体内增强双脱氧肌苷对劳氏鼠白血病病毒的活性。

In vitro and in vivo enhancement of ddI activity against Rauscher murine leukemia virus by ribavirin.

作者信息

Allen L B, Quenelle D C, Westbrook L, Taylor B A, Prichard M N, Brazier A D, Hollingshead M G, Shannon W M

机构信息

Microbiology Research Department, Southern Research Institute, Birmingham, AL 35205, USA.

出版信息

Antiviral Res. 1995 Jun;27(3):317-23. doi: 10.1016/0166-3542(95)00018-h.

DOI:10.1016/0166-3542(95)00018-h

PMID:8540752

Abstract

Ribavirin has been reported to enhance the activity of ddI against HIV. We explored this enhancement of antiviral activity in Rauscher murine leukemia virus (RMuLV) models in vitro and in vivo. The significant finding in these studies was that combinations of the drugs exhibited virus titer reductions that were greater than would be expected if the drug interactions were simply additive. These effects were designated synergistic by the method of Prichard and Shipman (Prichard, M.N. and Shipman, C., Jr. (1990). A three-dimensional model to analyze drug-drug interaction, Antiviral Res. 14, 181-206). In addition to the antiviral synergy, we also observed some synergistic toxicity in the animal model.

摘要

据报道，利巴韦林可增强去羟肌苷对HIV的活性。我们在体外和体内的劳氏鼠白血病病毒（RMuLV）模型中探究了这种抗病毒活性的增强情况。这些研究中的重要发现是，药物组合所导致的病毒滴度降低程度大于药物相互作用仅为相加作用时的预期值。根据普里查德和希普曼的方法（普里查德，M.N.和希普曼，C.，Jr.（1990年）。一种分析药物相互作用的三维模型，《抗病毒研究》14，181 - 206），这些效应被认定为协同作用。除了抗病毒协同作用外，我们在动物模型中还观察到了一些协同毒性。